Synergy Pharma (SGYP -3.7%) slips despite presenting positive safety and efficacy results from trials of plecanatide, its drug candidate for patients with chronic idiopathic constipation at an industry conference earlier in Orlando, Florida. The data showed the best improvement in symptoms were observed in patients receiving 3-milligram doses of plecanatide.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs